Prezista oral suspension launched

Prezista (darunavir) is now available as a 100mg/ml oral suspension.

Prezista (darunavir) is licensed for use in all adult patients as well as in antiretroviral treatment-experienced paediatric patients aged 3 years and over who weigh at least 15kg
Prezista (darunavir) is licensed for use in all adult patients as well as in antiretroviral treatment-experienced paediatric patients aged 3 years and over who weigh at least 15kg

Prezista (darunavir) is indicated in combination with low dose ritonavir and together with other antiretrovirals for the treatment of HIV-1 infection.

It may be used to administer doses to paediatric patients or in adult patients unable to swallow tablets.

View Prezista drug record

Further information: Janssen-Cilag Ltd

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.